Brentuximab Vedotin plus CHP as first-line therapy for CD30-positive peripheral T-cell lymphoma in Spain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects real-world data from multiple Spanish centers on adults with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP as their first-line treatment. Researchers use existing medical records to assess outcomes such as progression-free survival, overall response, overall survival, and treatment-related adverse events, including neuropathy and neutropenia. The study aims to describe how BV-CHP performs in routine practice outside of clinical trials. Participation is restricted to patients treated between January 2019 and September 2024, with no prior lymphoma treatment or prior use of BV-CHP in a trial context. Data are gathered from several hospitals to reflect real-world applicability across diverse centers in Spain.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of CD30-positive peripheral T-cell lymphoma, including anaplastic large cell lymphoma (ALK-positive, ALK-negative, breast implant-associated), peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma.
* Patients 18 years of age or older at the time of treatment with BV-CHP.
* Patients treated with brentuximab vedotin plus CHP as first-line therapy between January 2019 and September 2024

Exclusion Criteria:

* Patients who have received prior treatment for their lymphoma
* Patients who have received the combination as part of a clinical trial.

Where it's running

• Hospital Universitario A Coruña
  A Coruña, A Coruña, Spain Recruiting
• Hospital Universitari Son Llàtzer
  Palma de Mallorca, Balearic Islands, Spain Recruiting
• Hospital Universitari Son Espases
  Palma de Mallorca, Balearic Islands, Spain Recruiting
• ICO Hospital Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital del Mar
  Barcelona, Barcelona, Spain Recruiting
• Hospital Universitari Vall d'Hebron
  Barcelona, Barcelona, Spain Recruiting

Study contacts

• Study coordinator: Eva Domingo Domenech, MD
• Email: edomingo@iconcologia.net
• Phone: 932697750

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chidamide plus brentuximab vedotin for CD30-positive peripheral T‑cell lymphoma in patients unfit for chemotherapy

  This treatment will test whether combining chidamide with brentuximab vedotin helps people with CD30-positive peripheral T‑cell lymphoma who cannot tolerate standard chemotherapy.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07074457

• BrECADD for stage 2B–III classical Hodgkin lymphoma

  This tests the BrECADD chemotherapy combination in adults 18–60 with stage 2B (with risk factors) or stage III classical Hodgkin lymphoma and uses ctDNA to help track treatment response.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07002216

• Combining brentuximab vedotin with standard chemotherapy for Hodgkin lymphoma in adults

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help adults with untreated Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 4 Takeda · Vijayawada, Andhra Pradesh and 10 other locations · NCT06831370

• Using Brentuximab Vedotin to treat newly diagnosed Classical Hodgkin Lymphoma in young patients

  This study is testing if a new treatment with Brentuximab vedotin can help young patients with newly diagnosed classical Hodgkin lymphoma feel better while reducing the need for chemotherapy and radiation.

  Recruiting Phase 2/3 Children's Cancer Group, China · Shanghai · NCT06563245

• Comparing standard therapy to immunotherapy for early stage Hodgkin lymphoma

  This study is testing if adding immunotherapy to standard chemotherapy helps people with early stage Hodgkin lymphoma live longer and stay cancer-free.

  Recruiting at 404 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 418 other locations · NCT05675410

• New treatment approach for relapsed or refractory Hodgkin lymphoma

  This study is testing a new treatment for people with relapsed or hard-to-treat Hodgkin lymphoma to see if combining certain therapies can help them live longer and feel better.

  Recruiting Phase 2/3 Hospital Regional de Alta Especialidad del Bajio · León, Guanajuato · NCT05595447

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.